Japan Grants Patent to Brainstorm Covering Technique for NurOwn

The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal stem cells (MSCs). Through this technique, researchers can harness MSCs directly from a patient and mature them into cells that produce high levels of neurotrophic factors, which are compounds that […]

Brainstorm Cell Therapeutics : Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer’s Disease Program

NEW YORK, July 8, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader (KOL) webinar on its Alzheimer’s Disease (AD) program today at 8:15 AM Eastern Time. The Company recently announced that it is expanding its clinical pipeline to develop NurOwn® and begin […]

200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy

Patient dosing has finished in the pivotal Phase 3 trial assessing the safety and efficacy of repeat administrations of NurOwn, a cell-based therapy for people with amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics, the therapy’s developer, announced. The Phase 3 trial (NCT03280056), which enrolled about 200 participants, is underway at six U.S. sites: the University of California, Irvine; Cedars-Sinai Medical Center; California Pacific Medical Center; Massachusetts General Hospital; […]

BrainStorm to study stem cell treatment in Alzheimer’s patients

TEL AVIV (Reuters) – BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer’s disease. The U.S.-Israeli company is already conducting advanced trials of its treatment called NurOwn in patients with the neurodegenerative disease amyotrophic lateral sclerosis (ALS). MORE…


$500,000 Grant from ALS Association and I AM ALS On June 9, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced a combined grant of $500,000 from the ALS Association and I AM ALS to support an ALS biomarker study utilizing samples and data from the ongoing Phase 3 clinical trial of NurOwn® in ALS patients. The goal of […]

NurOwn May Curb Damaging Brain Inflammation in ALS Patients, Study Suggests

NurOwn, a cell-based therapy that protects and helps repair nerve cells, also may be able to curb the damaging brain inflammation that contributes to the progression of amyotrophic lateral sclerosis (ALS), recent findings suggest. Researchers believe this newly-found potential may extend the benefits of NurOwn in ALS patients and possibly among those with other conditions. […]


BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized 1:1 to receive NurOwn® or placebo in the randomized, double blind, placebo controlled, multi-dose trial. Cells were extracted once from each patient prior to treatment, […]

The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense’s product for ALS patients.

HERZLIYA, Israel, Feb. 6, 2020 /PRNewswire/ — NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation of two clinical studies to evaluate the benefit of PrimeC for ALS patients. A Phase IIa study is being conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC), by Prof. Vivian Drory. A similar […]